SANGUINE CORP. (SGNC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike Ankley who wrote (3360)	7/18/1998 4:38:00 AM
From: Mike Ankley	of 5402

Green Cross assigned U.S. patent 4,605,786 Perfluoro ether compound containing perfluorocycloalkyl moiety patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. ------------------------------------------------------------------------ Abstract ------------------------------------------------------------------------ A perfluoroether compound having the following formula is useful as a thermostable, inert solvent and inter alia as an oxygen carrier in an artificial blood or infusion fluid. ##STR1## wherein Rf(1) and Rf(2) are different from each other and are selected from the group of a C(1) or C(3) perfluoroalkyl group which may be interrupted by an oxygen atom, and a C(5) -C(7) perfluorocycloalkyl group, and n and n' are zero or an integer of 1; one of Rf(1) and Rf(2) being the C(5) -C(7) perfluorocycloalkyl group and the total number of carbon atoms being 9-11 inclusive. Cheers Mike

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next